Tectonic Therapeutic is a clinical-stage company developing TX45, a relaxin-based drug for pulmonary hypertension caused by heart failure, a condition with no approved treatment; TX45 is not approved.
Tectonic's case rests on TX45, a long-acting relaxin fusion protein given under the skin, in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF), which has no approved drug. The APEX Phase 2 enrolled 191 patients, 137 in the more severe CpcPH group used for its primary endpoint, change in pulmonary vascular resistance; a July safety review found no reason to change the trial. Results are expected in early Q1 2027. Cash of $227.1 million is guided to last into Q1 2029.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: APEX lowers lung-vessel resistance in CpcPH
Does TX45 lower pulmonary vascular resistance in patients with CpcPH?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
TX45's APEX Phase 2 results in early Q1 2027 test lung-vessel resistance in PH-HFpEF
TX45's Phase 2 PVR readout in CpcPH will determine whether Tie2 agonism translates to a registrational path in a disease space dominated by established vasodilator classes
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung and respiratory diseases, Autoimmune and inflammatory diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.